Repeated High Dosage Naloxone Treatment without Therapeutic Efficacy in Schizophrenic Patients*

Leibl, K

doi:10.1055/s-2007-1017446

Cited by 10 publications

(3 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The third group of naloxone studies consists of 7 studies that used doses above 10 mg, ranging from 20 mg to 2 mg/kg. Similar to results of studies in the second group, results of these studies showed that persons who received IV administration of naloxone tended to demonstrate significant improvement on BPRS (44)(45)(46), while those who received subcutaneous or intramuscular administration showed mixed results (47)(48)(49)(50).…”

Section: Naloxone Trialssupporting

confidence: 74%

The Role of Dynorphin and the Kappa Opioid Receptor in the Symptomatology of Schizophrenia: A Review of the Evidence

Clark

Abi‐Dargham

2019

Biological Psychiatry

View full text Add to dashboard Cite

Schizophrenia is a debilitating mental illness that affects approximately 1% of the world's population. Despite much research in its neurobiology to aid in developing new treatments, little progress has been made. One system that has not received adequate attention is the kappa opioid system and its potential role in the emergence of symptoms, as well as its therapeutic potential. Here we present an overview of the kappa system and review various lines of evidence derived from clinical studies for dynorphin and kappa opioid receptor involvement in the pathology of both the positive and negative symptoms of schizophrenia. This overview includes evidence for the psychotomimetic effects of kappa opioid receptor agonists in healthy volunteers and their reversal by the pan-opioid antagonists naloxone and naltrexone and evidence for a therapeutic benefit in schizophrenia for 4 pan-opioid antagonists. We describe the interactions between kappa opioid receptors and the dopaminergic pathways that are disrupted in schizophrenia and the histologic evidence suggesting abnormal kappa opioid receptor signaling in schizophrenia. We conclude by discussing future directions.

show abstract

Section: Naloxone Trialssupporting

confidence: 74%

The Role of Dynorphin and the Kappa Opioid Receptor in the Symptomatology of Schizophrenia: A Review of the Evidence

Clark

Abi‐Dargham

2019

Biological Psychiatry

View full text Add to dashboard Cite

show abstract

“…The potential therapeutic use of opioid antagonists in schizophrenia has been investigated since the late 1970s (Berger, Watson, Akil, & Barchas, 1981; Davis, Buchsbaum, van Kammen, & Bunney, 1979; Davis et al, 1977; Gitlin, Gerner, & Rosenblatt, 1981; Gunne, Lindstrom, & Terenius, 1977; Kurland, McCabe, Hanlon, & Sullivan, 1977; Naber & Leibl, 1983; Pickar et al, 1982; Pickar et al, 1989; Ragheb, Berney, & Ban, 1980; Verhoeven, van Praag, & van Ree, 1984; Volavka, Mallya, Baig, & Perez-Cruet, 1977; Watson, Berger, Akil, Mills, & Barchas, 1978). This interest was fueled by findings indicating that a reduction in abnormally elevated opioid levels correlated with clinical improvement in schizophrenics (Terenius et al, 1976).…”

Section: Schizophreniamentioning

confidence: 99%

Clinical uses of naltrexone: A review of the evidence.

Modesto‐Lowe¹,

Kirk²

2002

Experimental and Clinical Psychopharmacology

View full text Add to dashboard Cite

The implication of the opioidergic system in the pathogenesis of various substance use disorders has led to renewed interest in expanding the clinical uses of naltrexone, an opioid antagonist. This article examines the evidence for the efficacy of naltrexone in a variety of substance use and psychiatric disorders. Naltrexone can be an effective treatment for alcohol and opioid dependence if issues of compliance are adequately addressed. Thus far, no definitive role has been found for naltrexone in the treatment of other psychiatric disorders. Further research needs to be done in self-injurious behavior, gambling, cocaine, and nicotine dependence.

show abstract

“…Recently, naloxone was administered double-blind controlled in a cross-over design for 4 days at a dosage of 20 mg/day to six schizophrenic patients. Again, apart from a slight drowsiness, naloxone was without any significant effect (38). The report on normal volunteers that high doses of naloxone (2 and 4 mg/kg) caused irritability, anxiety and tension (39) confirms that the opiate antagonist is a psychotropic drug; however, its therapeutic efficacy in schizophrenia is doubtful.…”

Section: Discussionmentioning

confidence: 87%

Naloxone treatment for five days ineffective in schizophrenia

Münch¹,

Wissmann²,

Grosse³

et al. 1983

Acta Psychiatr Scand

Self Cite

View full text Add to dashboard Cite

show abstract

Repeated High Dosage Naloxone Treatment without Therapeutic Efficacy in Schizophrenic Patients*

Abstract: 6 schizophrenic patients were treated in a cross-over design for 4 days each with 20 mg naloxone or placebo. No patient showed a significant change of his or her psychotic behaviour. This result is not in agreement with an antipsychotic action of the opiate antagonist.

Cited by 10 publications

References 13 publications

The Role of Dynorphin and the Kappa Opioid Receptor in the Symptomatology of Schizophrenia: A Review of the Evidence

The Role of Dynorphin and the Kappa Opioid Receptor in the Symptomatology of Schizophrenia: A Review of the Evidence

Clinical uses of naltrexone: A review of the evidence.

Naloxone treatment for five days ineffective in schizophrenia

Contact Info

Product

Resources

About